公司2024 年业绩超市场预期，并上调阿美乐2025 年销售/峰值销售指引至60亿/80 亿元人民币。我们上调盈利预测、上调目标价至24.60 港元。2024 年业绩超市场预期，阿美乐表现亮眼：收入和净利润分别增长21.3%/33.4%至123 亿/43.7 亿元（人民币，下同），符合我们的预期但超市场预期；全年派息率42%。创新药收入95 亿元，其中产品收入约80 亿元（同比+28.5%），对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.